Paul Covington

Summary

Publications

  1. pmc Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients
    David A Andrae
    Furiex Pharmaceuticals, Inc, 3900 Paramount Parkway, Suite 150, Morrisville, NC 27560, USA
    Health Qual Life Outcomes 11:208. 2013
  2. pmc Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection
    Paul Covington
    Furiex Pharmaceuticals Inc, 3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560, USA
    Antimicrob Agents Chemother 55:5790-7. 2011

Collaborators

  • David A Andrae
  • Donald L Patrick
  • Douglas A Drossman

Detail Information

Publications3

  1. pmc Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients
    David A Andrae
    Furiex Pharmaceuticals, Inc, 3900 Paramount Parkway, Suite 150, Morrisville, NC 27560, USA
    Health Qual Life Outcomes 11:208. 2013
    ..The current paper assesses this previously-validated instrument employing data collected from 754 patients who participated in a randomized clinical trial of a novel treatment, eluxadoline, for IBS-d...
  2. pmc Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection
    Paul Covington
    Furiex Pharmaceuticals Inc, 3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560, USA
    Antimicrob Agents Chemother 55:5790-7. 2011
    ..e., lack of spread of lesions and absence of fever at 48 to 72 h), and (ii) cure rates for ABSSSI pathogens (especially MRSA) consistent with the historical literature...